OncoBEAM RAS CRC Kit CE-IVD

myProbes is a custom design and manufacture service that provides unique fluorescence in situ hybridisation (FISH) probes using the BAC-2-FISH™ process. This process utilises Cytocell’s proprietary BAC clone collection containing >220,000 clones to produce fully quality-assured custom FISH probes for virtually any sequence in the entire human genome.

Category:

The Sysmex way of liquid biopsy: Sysmex Inostics OncoBEAM

Sysmex Inostics has been the pioneer in liquid biopsy by introducing OncoBEAM into the clinical routine. OncoBEAM combines emulsion digital PCR with flow cytometry to provide highly sensitive mutation detection based upon ctDNA isolated from blood samples. Thereby it offers new possibilities for cancer management & clinical research.

OncoBEAM RAS CRC Kit CE-IVD

  • Detection of 34 RAS mutations 16 mutations in KRAS codons 12, 13, 59, 61, 117, 146 and 18 mutations in NRAS codons 12, 13, 59, 61, 117, 146 – in cell-free DNA extracted from 3 mL of plasma

  • The Test is intended to aid clinicians in determining the potential benefit of anti-epidermal growth factor receptor (EGFR) therapy for colorectal cancer patients

  • High concordance with tissue results

  • Rapid turnaround time from biopsy to result, minimally invasive

  • Accurate real-time information, no selection bias

*Availability dependent on local country regulatory status.

The OncoBEAM Advantage

  • Reliable detection of mutations from cell-free DNA that occur at mutant allele frequencies (MAF) as low as 0.01%
  • Viable alternative to tissue testing due to its high concordance (>90%) with tissue biopsy
  • Timely and minimally-invasive analysis of specific mutations before or during targeted therapy
+ Features & Benefits

The OncoBEAM Advantage

  • Reliable detection of mutations from cell-free DNA that occur at mutant allele frequencies (MAF) as low as 0.01%
  • Viable alternative to tissue testing due to its high concordance (>90%) with tissue biopsy
  • Timely and minimally-invasive analysis of specific mutations before or during targeted therapy
+ More information